Please assess the completion status of the following clinical trial:

Trial Title: Hemostasis With QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing cardiac catheterization (CC) and/or percutaneous coronary intervention (PCI) via the radial artery as part of their standard of care treatment~2. Patients able and willing to give written informed consent~3. Patient \> 18 years of age~Exclusion Criteria:~1. Patients presenting with acute ST-segment elevation myocardial infarction (STEMI)~2. Oral anticoagulation therapy as described below:~   1. If on a DOAC (direct-acting oral anticoagulants - ie dabigatran, rivaroxaban, apixaban, edoxaban), patients will be excluded if DOAC taken within 48 hours and eGFR \> 30 ml/min or DOAC taken within 72 hours and eGFR \< 30 ml/min.~  2. If the patient is on warfarin, excluded if INR \> 1.5~3. Liver Failure~4. Life-threatening illness that the patient would not be expected to live more than 6 months post-procedure~5. Major unanticipated event in the cardiac cath lab (i.e. cardiac arrest) of an already consented patient, but before randomization, where the operator believes participation in this trial is now inappropriate.~6. Thrombocytopenia, with a platelet count of \< 75,000.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: NO_INTERVENTION): TR Band inflated with 10 mL of air, followed by gradual weaning over the subsequent 60 minutes.
- Arm 2 (Type: EXPERIMENTAL): QC pad with a Coban bandage to hold the pad in place to achieve hemostasis.
- Arm 3 (Type: EXPERIMENTAL): QC pad with a Tegaderm dressing to hold the pad in place to achieve hemostasis.
- Arm 4 (Type: EXPERIMENTAL): QC pad with a TR Band to hold the pad in place to achieve hemostasis.

Based on this trial design, predict the completion outcome and termination type (if applicable).